Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Impact of induced atrial fibrillation during atrioventricular nodal reentrant tachycardia ablation
Session:
Posters (Sessão 6 - Écran 3) - Arrítmias 7 - Fibrilhação Auricular 2
Speaker:
Ana Raquel Carvalho Santos
Congress:
CPC 2022
Topic:
C. Arrhythmias and Device Therapy
Theme:
05. Atrial Fibrillation
Subtheme:
05.9 Atrial Fibrillation - Other
Session Type:
Pósters Electrónicos
FP Number:
---
Authors:
Ana Raquel Carvalho Santos; Ana Lousinha; Madalena Coutinho Cruz; Guilherme Portugal; Paulo Osorio; Bruno Valente; Pedro Silva Cunha; Sérgio Laranjo; Margarida Paulo; Manuel Brás; Ana Sofia Delgado; Tiago Rosa; Helena Fonseca; Mário Martins Oliveira; Rui Cruz Ferreira
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Ablation is the treatment of choice for atrioventricular nodal reentrant tachycardia (AVNRT). Atrial fibrillation (AF) can incidentally occur during this procedure, labeling these patients (P) as susceptible for AF in the future. Our aim was to assess the presence of new onset AF in P who presented this arrhythmia during the electrophysiological study (EPS).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Methods: We retrospectively analyzed 580 P that underwent AVNRT ablation between November 2008 and August 2020. Patients with previous AF were excluded. After having AF induced during the EPS, 62 P were identified as susceptible for developing AF. Data were collected by contacting P and consulting medical records.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Results: The studied population had 64.5% (n=40) females, 35.5% (n=22) males, with ages between 15 and 81years old (median 52.3, mean 50.1). At ablation date, 33.9% (n=21) had hypertension, 3.2% (n=2) diabetes, 6.5% (n=4) chronic kidney disease, 3.2% (n=2) obstructive sleep apnea, 6.5% (n=4) coronary artery disease and 6.5% (n=4) structural heart disease. Previously to ablation, 46.8% (n=29) were on beta-blocker, 1.6% (n=1) on amiodarone and 3.2% (n=2) on flecainide. When admitted to the procedure, 98.4% (n=61) were in sinus rhythm and 1.6% (n=1) had a pacemaker. “Slow-fast” was the most common AVNRT type (96.8%). During the EPS, other arrhythmias were induced: in 12.9% (n=8) atrial flutter and in 9.7% (n=6) atrial tachycardia. After AF induction, 12.9% (n=8) needed electrical cardioversion and 3.2% (n=2) needed both electrical and pharmacological. At the time of ablation, transient complete atrioventricular block was noted in 6.5% (n=4) P. When contacted, 100% (n=62) had 1 year of follow-up, 69.4% (n=43) 5 years and 25.8% (n=16) 10 years, with a mean follow-up of 6.6 years. It was not possible to contact 12.9% (n=8) of the P, of those, 6.5% (n=4) died and 6.5% (n=4) did not reply. Recurrence of AVNRT was documented in 6.4% (n=4) P and all underwent a successful second ablation. Almost one third, 32.3% (n=20), were symptomatic, mainly with palpitations, and 27.4% (n=17) maintained follow up with a Cardiologist. New-onset AF was documented in 1 P only (1.6%), diagnosed 9 years after the procedure.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Conclusion: In our cohort, the induction of AF during EPS did not translate into clinical AF during follow-up. Whether this is a nonspecific finding related to catheter manipulation or pacing maneuvers on pharmacological provocation deserves further investigation. </span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site